A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis (DR-TB) and provide access to effective cure and prevention of DR-TB throughout the world.

Over ten million people will develop tuberculosis (TB) in the world this year; over 500,000 of these will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and regimens involving new TB drugs in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

 


Developments in MDR-TB


50th Union World Conference on Lung Health: Prevention trial targets multidrug-resistant TB

Posted on 11/14/19

HYDERABAD, INDIA – The National Institute of Allergy and Infectious Diseases is investing $70 million in a phase III clinical trial assessing the use of tuberculosis treatments in preventing multidrug-resistant tuberculosis infection among high-risk individuals, including infected household contacts of MDR-TB patients and people living with HIV, institute officials announced here.

Heated debate on access to TB drugs at global meet

Posted on 11/14/19

With the government providing key drugs like bedaquiline to only public sector patients, doctors say private patients have equal right to treatment without spending out of pocket.

For more news, click here.